Top-Rated StocksTop-RatedNASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $12.06 +0.06 (+0.50%) Closing price 04:00 PM EasternExtended Trading$12.08 +0.01 (+0.12%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bicara Therapeutics Stock (NASDAQ:BCAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$11.57▼$12.1350-Day Range$8.71▼$12.0652-Week Range$7.80▼$28.09Volume199,254 shsAverage Volume275,067 shsMarket Capitalization$657.99 millionP/E RatioN/ADividend YieldN/APrice Target$32.25Consensus RatingBuy Company Overview Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect. The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder. Both programs are supported by preclinical validation and early-stage clinical data demonstrating target engagement and potential improvements in mood and social functioning. Bicara’s pipeline leverages translational biomarkers to guide dose selection and patient stratification in ongoing studies. Founded in 2020 and headquartered in Cambridge, Massachusetts, Bicara Therapeutics completed its initial public offering on the Nasdaq in 2021. The company’s management team brings together experienced leaders from neuroscience, endocrinology and pharmaceutical development. Bicara also collaborates with academic centers and contract research organizations to accelerate its clinical programs and expand the understanding of neurohormone mechanisms in human disease. Looking ahead, Bicara plans to advance its lead candidates through proof-of-concept studies while exploring additional neurohormone targets for depression, anxiety and other central nervous system indications. By combining peptide chemistry with intranasal formulations, the company aims to address significant unmet needs in mental health and to establish a new class of therapeutics with improved efficacy and tolerability profiles.AI Generated. May Contain Errors. Read More Bicara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreBCAX MarketRank™: Bicara Therapeutics scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBicara Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Bicara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicara Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicara Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicara Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bicara Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCAX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicara Therapeutics does not currently pay a dividend.Dividend GrowthBicara Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BCAX. News and Social Media3.0 / 5News Sentiment1.36 News SentimentBicara Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.Search Interest1 people have searched for BCAX on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bicara Therapeutics' insider trading history. Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAX Stock News HeadlinesBicara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comHC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $40.00August 25, 2025 | americanbankingnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 4 at 2:00 AM | American Alternative (Ad)Bicara Therapeutics price target lowered to $40 from $41 at H.C. WainwrightAugust 22, 2025 | msn.comPiper Sandler Initiates Coverage of Bicara Therapeutics (BCAX) with Overweight RecommendationAugust 19, 2025 | msn.comBicara Therapeutics initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comBicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deBicara Therapeutics reports Q2 EPS (50c), consensus (54c)August 13, 2025 | msn.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 30.8% and is now trading at $12.06. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share. Who are Bicara Therapeutics' major shareholders? Bicara Therapeutics' top institutional shareholders include Vestal Point Capital LP (9.16%), Geode Capital Management LLC (1.23%), Bank of America Corp DE (0.83%) and Schroder Investment Management Group (0.78%). View institutional ownership trends. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2025Today9/04/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Price Target for Bicara Therapeutics$32.25 High Price Target$48.00 Low Price Target$8.00 Potential Upside/Downside+168.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.67% Return on Assets-20.89% Debt Debt-to-Equity RatioN/A Current Ratio25.80 Quick Ratio25.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.98 per share Price / Book1.51Miscellaneous Outstanding Shares54,563,000Free FloatN/AMarket Cap$656.67 million OptionableN/A BetaN/A Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:BCAX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.